Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
type 1 diabetes is an autoimmune disease and still, some unknown mechanisms are undiscovered
millions of children and adults suffer from this type which need basal-bolus insulin as the
classical regimen, and basal-bolus insulin is the best type of treatment is similar to the
physiological pattern, so our target and may studies before how to preserve the residual beta
cells or postpone the complete destruction or extend the honeymoon stage to improve quality
of life, the most challenge at type 1 diabetes is diabetic ketoacidosis which affect the
quality of life and risk of death so at our clinical trials using the combination of basal
insulin-like degludec as its action extend to 72 hours and has high flexibility and less
hypoglycemic events and has an affinity to 99% to albumin so may be considered the most type
of insulin is similar to human physiological insulin as 50% of insulin pass through portal
circulation so no insulin until now it is mimic the normal physiological insulin but IDeg is
the nearest to normal until now, Objective: To compare the efficacy and safety of basal-bolus
insulin degludec and semaglutide with regular standard of care versus basal-bolus insulin
with regular standard of care in early type 1 diabetic patients.
In our study, the investigators will compare 2 groups of early type 1 patients in the age
group 18 years to 35 years Protocol and Methodology for a Randomized Controlled Trial of
Basal-Bolus Insulin Degludec and Semaglutide with Regular Standard of Care Versus Basal-Bolus
Insulin with Regular Standard of Care in Early Type 1 Diabetic Patients
Study Design: Randomized, controlled, open-label trial
Setting: Outpatient diabetes clinics
Participants: Early type 1 diabetic patients (aged 18-35 years) who have been diagnosed with
type 1 diabetes for less than 2 years and have a hemoglobin A1c (HbA1c) of 7.0-11%.
the tests will be done pre- and post :
1. Anti GAD 65 and anti IA2
2. HA1C
3. Serum C peptide
4. fasting insulin
5. serum zinc